Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(25%)
Results Posted
100%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
2
50%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 22 (50.0%)

Trials by Status

terminated125%
completed250%
recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_2

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer

NCT05771584
terminatedphase_2

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

NCT05163223
completedphase_1

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)

NCT01704781
completedphase_1

Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir

NCT02092116

Clinical Trials (4)

Showing 4 of 4 trials
NCT05771584Phase 2

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer

Recruiting
NCT05163223Phase 2

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

Terminated
NCT01704781Phase 1

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)

Completed
NCT02092116Phase 1

Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4